Sorafenat 200mg Natco Therapeutic indications: Sorafenat 200mg Tablets is indicated for the treatment of hepatocellular carcinoma for the treatment of patients with advanced renal cell carcinoma who have not responded to, or are not eligible for, interferon-alfa or interleukin-2 therapy for the treatment of differentiated thyroid carcinoma (Papillary / follicular / Hurthle cells) progressively, locally advanced or metastatic, refractory to radioiodine treatment. Contraindications, precautions: Treatment with Sorafenat will be performed under the supervision of a specialist in anticancer therapy. Dosage and administration : The recommended dose for adults is 400 mg sorafenib (two 200 mg tablets) twice daily (equivalent to a total daily dose of 800 mg) under the supervision of a specialist in anticancer therapy.
Disclaimer : This information should not be used to decide whether or not to take this Product or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this Product . It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this product.